Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have received an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $51.75.
Several equities analysts recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research note on Monday. JPMorgan Chase & Co. increased their price target on Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd.
Read Our Latest Stock Report on VERA
Insider Activity at Vera Therapeutics
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in VERA. Avoro Capital Advisors LLC acquired a new stake in shares of Vera Therapeutics during the first quarter worth $227,027,000. Kynam Capital Management LP grew its holdings in Vera Therapeutics by 23.5% during the 4th quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock worth $56,142,000 after acquiring an additional 694,286 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in Vera Therapeutics during the 1st quarter worth about $103,189,000. Vanguard Group Inc. raised its position in shares of Vera Therapeutics by 31.5% in the 1st quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock worth $92,653,000 after acquiring an additional 515,106 shares in the last quarter. Finally, Samlyn Capital LLC lifted its stake in shares of Vera Therapeutics by 90.8% in the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after purchasing an additional 586,410 shares during the period. Institutional investors own 99.21% of the company’s stock.
Vera Therapeutics Price Performance
Vera Therapeutics stock opened at $40.02 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43. Vera Therapeutics has a 52 week low of $9.24 and a 52 week high of $50.78. The stock has a market capitalization of $2.19 billion, a P/E ratio of -19.52 and a beta of 0.99. The stock has a fifty day moving average of $37.18 and a 200-day moving average of $39.08.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, sell-side analysts expect that Vera Therapeutics will post -2.59 earnings per share for the current fiscal year.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Further Reading
- Five stocks we like better than Vera Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- How to Invest in the FAANG Stocks
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Business Services Stocks Investing
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.